Drug Profile
Research programme: antiemetic therapeutics - InnoPharma
Alternative Names: IP-123Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator InnoPharma Inc
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Nausea and vomiting
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Nausea and vomiting in USA (Parenteral, Injection)
- 25 Sep 2014 InnoPharma Inc has been acquired by Pfizer
- 21 Jul 2014 Preclinical development is ongoing in USA